Therapeutic approaches to non-alcoholic fatty liver disease: past achievements and future challenges

被引:38
作者
Xiao, Jia [1 ,4 ]
Guo, Rui [1 ]
Fung, Man Lung [2 ,3 ]
Liong, Emily C. [1 ]
Tipoe, George L. [1 ,3 ]
机构
[1] Univ Hong Kong, Li Ka Shing Fac Med, Dept Anat, Hong Kong, Hong Kong, Peoples R China
[2] Univ Hong Kong, Li Ka Shing Fac Med, Dept Physiol, Hong Kong, Hong Kong, Peoples R China
[3] Univ Hong Kong, Li Ka Shing Fac Med, Res Ctr Heart Brain Hormone & Hlth Aging Ctr, Hong Kong, Hong Kong, Peoples R China
[4] Chinese Acad Sci, Shenzhen Inst Adv Technol, Gene & Cell Engn Res Ctr, Shenzhen, Peoples R China
关键词
non-alcoholic fatty liver disease; therapy; pharmaceuticals; exercise; PLACEBO-CONTROLLED-TRIAL; HEPATIC INSULIN-RESISTANCE; ACTIVATED PROTEIN-KINASE; COA REDUCTASE INHIBITORS; LIFE-STYLE MODIFICATION; DIET-INDUCED-OBESITY; ALL-CAUSE MORTALITY; VITAMIN-E; ADIPOSE-TISSUE; RISK-FACTORS;
D O I
10.1016/S1499-3872(13)60021-1
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is a leading cause of chronic liver injury and mortality in Western countries and China. However, as to date, there is no direct and effective therapy for this disease. The aim of this review is to analyze the key progress and challenges of main current therapeutic approaches in NAFLD. DATA SOURCE: We carried out a PubMed search of English-language articles relevant to NAFLD therapy. RESULTS: There are two major therapeutic strategies for NAFLD treatment: (1) lifestyle interventions (including weight reduction, dietary modification and physical exercise) and (2) pharmaceutical therapies. Lifestyle interventions, particularly chronic and moderate intensity exercise, are the most effective and recognized clinical therapies for NAFLD. For pharmaceutical therapies, although their effects and mechanisms have been extensively investigated in laboratory studies, they still need further tests and investigations in clinical human trials. CONCLUSION: Future advancement of NAFLD therapy should focus on the mechanistic studies on cell based and animal models and human clinical trials of exercise, as well as the combination of lifestyle intervention and pharmaceutical therapy specifically targeting main signaling pathways related to lipid metabolism, oxidative stress and inflammation. (Hepatobiliary Pancreat Dis Int 2013;12:125-135)
引用
收藏
页码:125 / 135
页数:11
相关论文
共 123 条
[11]  
Bistrian BR, 2012, JAMA-J AM MED ASSOC, V308, P1088, DOI 10.1001/2012.jama.11614
[12]   The major green tea polyphenol, (-)-epigallocatechin-3-gallate, inhibits obesity, metabolic syndrome, and fatty liver disease in high-fat-fed mice [J].
Bose, Mousumi ;
Lambert, Joshua D. ;
Ju, Jihyeung ;
Reuhl, Kenneth R. ;
Shapses, Sue A. ;
Yang, Chung S. .
JOURNAL OF NUTRITION, 2008, 138 (09) :1677-1683
[13]   Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity [J].
Browning, JD ;
Szczepaniak, LS ;
Dobbins, R ;
Nuremberg, P ;
Horton, JD ;
Cohen, JC ;
Grundy, SM ;
Hobbs, HH .
HEPATOLOGY, 2004, 40 (06) :1387-1395
[14]   Green tea extract protects leptin-deficient, spontaneously obese mice from hepatic steatosis and injury1,2 [J].
Bruno, Richard S. ;
Dugan, Christine E. ;
Smyth, Joan A. ;
DiNatale, Dana A. ;
Koo, Sung I. .
JOURNAL OF NUTRITION, 2008, 138 (02) :323-331
[15]   Bariatric surgery worldwide 2003 [J].
Buchwald, H ;
Williams, SE .
OBESITY SURGERY, 2004, 14 (09) :1157-1164
[16]   Resveratrol inhibits nonalcoholic fatty liver disease in rats [J].
Bujanda, Luis ;
Hijona, Elizabeth ;
Larzabal, Mikel ;
Beraza, Marta ;
Aldazabal, Pablo ;
Garcia-Urkia, Nerea ;
Sarasqueta, Cristina ;
Cosme, Angel ;
Irastorza, Belen ;
Gonzalez, Alberto ;
Arenas, Juan I., Jr. .
BMC GASTROENTEROLOGY, 2008, 8 (1)
[17]  
Capristo E, 2005, Eur Rev Med Pharmacol Sci, V9, P265
[18]   Resveratrol: French paradox revisited [J].
Catalgol, Betul ;
Batirel, Saime ;
Taga, Yavuz ;
Ozer, Nesrin Kartal .
FRONTIERS IN PHARMACOLOGY, 2012, 3
[19]   Statins and hepatotoxicity: Focus on patients with fatty liver [J].
Chalasani, N .
HEPATOLOGY, 2005, 41 (04) :690-695
[20]   The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology [J].
Chalasani, Naga ;
Younossi, Zobair ;
Lavine, Joel E. ;
Diehl, Anna Mae ;
Brunt, Elizabeth M. ;
Cusi, Kenneth ;
Charlton, Michael ;
Sanyal, Arun J. .
GASTROENTEROLOGY, 2012, 142 (07) :1592-1609